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Maternal asthma represents a significant burden to individuals and the healthcare system, 23 
affecting 1 in 10 pregnancies worldwide. Approximately 50% of asthmatic women 24 
experience a deterioration of asthma control at some stage during pregnancy, with a number 25 
requiring use of oral corticosteroids for the management of acute exacerbations. The presence 26 
of maternal asthma and exacerbations during pregnancy is a noted risk factor for a range of 27 
adverse perinatal outcomes including preterm birth, small-for-gestational age, pre-eclampsia, 28 
and gestational diabetes. These negative impacts highlight the need for evidence-based 29 
approaches for improving asthma management during pregnancy and subsequent perinatal 30 
outcomes. Despite this, relatively small progress has been made in enhancing the 31 
management of maternal asthma in the clinical setting. A major challenge in improving 32 
outcomes of asthmatic pregnancies is that there is no single simplified approach for 33 
improving outcomes, but rather the requirement to consider the dynamic relationship between 34 
a myriad of interrelated factors that ultimately determine an individual’s ability to maintain 35 
adequate asthma control. Understanding how these factors are impacted by pregnancy and 36 
how they can be addressed through various interventions is therefore important in optimizing 37 
health outcomes. This review summarises key factors involved in influencing outcomes 38 
associated with maternal asthma. This includes an overview of the use of asthma medications 39 
in pregnancy, while also considering the impacts of interrelated aspects such as medication 40 
adherence, health-seeking behaviours, biological and lifestyle factors, co-morbidities, and 41 
asthma self-management strategies on asthma control. Addressing such factors through 42 
multidisciplinary approaches towards treatment have potential to improve the health of 43 
mothers and their offspring. Optimising asthma control should be a high priority within the 44 
antenatal setting, with women advised about the importance of good asthma control, 45 
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managing asthma actively throughout pregnancy by utilising their asthma medications, and 46 
managing exacerbations in a timely and effective manner. 47 
Key Words: Pregnancy; asthma; inhaled corticosteroids; medications 48 
  49 
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1. Introduction 50 
Maternal asthma represents a significant burden to individuals and the healthcare system. 51 
Asthma is one of the most common chronic medical conditions in pregnancy, complicating an 52 
estimated 8-13% of pregnancies worldwide.[1] There is clear evidence that maternal asthma is 53 
associated with significant perinatal morbidity and mortality, with 20-50% increased risk of 54 
adverse perinatal outcomes including low birth weight, small-for-gestational age, preterm 55 
birth, pre-eclampsia, and gestational diabetes.[2, 3] Given the increased risk of adverse 56 
pregnancy outcomes, it is perhaps not unsurprising that maternal asthma has also been 57 
associated with long-term adverse effects on the health of the offspring, including an increased 58 
risk of a wide spectrum of non-communicable diseases in the offspring.[4] 59 
These negative impacts highlight the need for evidence-based approaches for improving 60 
asthma management during pregnancy and subsequent perinatal outcomes. Despite this, only 61 
relatively small progress has been made in enhancing the management of maternal asthma in 62 
the clinical setting. A major challenge in improving outcomes of asthmatic pregnancies is that 63 
there is no single simplified approach for improving outcomes, but rather the requirement to 64 
consider the dynamic relationship between a myriad of interrelated factors that ultimately 65 
determine an individual’s ability to maintain adequate asthma control.  66 
Understanding how these factors are impacted on by pregnancy and how they can be 67 
addressed through various interventions is therefore important in optimizing health outcomes. 68 
For this reason, in this review we have chosen to provide an overview of what we believe to be 69 
some of key factors involved in influencing outcomes associated with maternal asthma. This 70 
involves looking beyond asthma medications and considering interrelated aspects such as 71 
health-seeking behaviours, asthma self-management, medication adherence, biological and 72 
lifestyle factors and co-morbidities. A description of the etiology, pathogenesis, and typical 73 
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management of asthma in general adults is beyond the scope of this review and can be found 74 
elsewhere.[5] 75 
2. Overview of asthma treatment in pregnancy 76 
The determination of safety of asthma medications in pregnancy is largely limited to 77 
observational studies, limiting the ability to precisely distinguish the impacts of asthma 78 
treatments from those of maternal asthma. Despite this challenge, there is a growing body of 79 
literature supporting the safety of various asthma medications during pregnancy, with a 80 
prevailing belief that uncontrolled asthma during pregnancy poses greater short and long-81 
term risk to the mother and her baby. A summary of asthma medications with respect to their 82 
usual doses, adverse events, and safety during pregnancy is presented in Table 1. The greatest 83 
amount of evidence exists for the use of inhaled corticosteroids in pregnancy, but there is 84 
increasing evidence to support the use of ICS combined with LABA.[6] Therefore there is no 85 
reason that women who enter pregnancy on a combined ICS + LABA should necessarily be 86 
switched to an ICS alone preparation. Existing recommendations are that asthma be managed 87 
during pregnancy in the same manner as a non-pregnant adult, including management of 88 
asthma medications.[7] This means selecting medication and delivery devices that meet 89 
patient’s needs and circumstances, with therapy divided into the use of long-term control 90 
medications to prevent asthma manifestations and the use of rescue therapy to provide 91 
immediate relief of symptoms. In accordance with non-pregnant adults, asthma control 92 
should be regularly assessed and preventer medications adjusted accordingly at regular 93 
intervals to maintain adequate symptom control. An approach towards the adjustment of 94 
asthma therapies in pregnancy is outlined in Figure 2. Given the high prevalence of poor 95 
medication adherence in pregnancy, it is critical that this aspect is evaluated prior to any 96 
recommendations to step up treatment. Further, among non-pregnant adults there is a general 97 
recommendation to consider stepping down therapy in situations where asthma is stable and 98 
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has been well controlled for 2-3 months, but evidence to support this strategy in pregnancy is 99 
very limited. Therefore consideration to stepping down treatment should only be considered 100 
if the woman is taking an inappropriately high dose of a medicine and should be done under 101 
careful supervision. 102 
 103 
 104 
3. Course of asthma in pregnancy 105 
Pregnancy is recognized as a major challenge in the management of asthma as it can alter 106 
the course of asthma severity and its treatment, which in turn has the potential to influence 107 
pregnancy outcomes. Recent data demonstrates that half of all women experience a loss of 108 
asthma control during pregnancy, with approximately 1 in 5 experiencing a moderate to 109 
severe exacerbation.[8] Explanations for this clinical observation are unclear, but could relate 110 
to a range of interconnecting factors, as outlined in Figure 1. Outside of pregnancy, it is well 111 
recognised that a number of factors impact on asthma control. Each of these factors in turn 112 
can be influenced by pregnancy, providing some explanation for changes in asthma control. 113 
For example, pregnancy is a time of significant change, including physiological, behavioural, 114 
and biological, with women interacting with the healthcare system with significantly greater 115 
frequency than they likely did prior to pregnancy. The impact of each of these factors on 116 
asthma management is outlined below. 117 
 118 
3.1.Medication adherence  119 
While the continuation of usual asthma medications during pregnancy is recommended in 120 
clinical guidelines, it is not uncommon for women to cease their asthma medications, with or 121 
without consultation with healthcare professionals.[9] This is of significant concern given that 122 
Author’s Post-Print Version; Copyright – Pharmacol Res; doi: 10.1016/j.phrs.2017.12.019 
7 
 
non-adherence to medication has been identified as a key factor involved in worsening asthma 123 
during pregnancy.[10] Decisions regarding the cessation of asthma medications during 124 
pregnancy may be driven through a perceived lack of benefit in continuing medications, 125 
insufficient support and education from healthcare professionals regarding the use of asthma 126 
medications during pregnancy, or concerns regarding the safety of asthma medications during 127 
pregnancy.[11] In the prospective cohort study by Murphy et al. 40% of women reported non-128 
adherence to inhaled corticosteroids. [12] Reduced medication adherence to short-acting beta-129 
agonists may also be a concern in pregnancy, but data relating to the potential extent of this 130 
problem are not available. 131 
 132 
3.2 Healthcare provider interaction 133 
Generally speaking, pregnancy presents an opportunity for women to interact with the 134 
healthcare system at a greater frequency than they would have previously. Increased 135 
interaction with healthcare providers means increased opportunity to evaluate and advise on 136 
asthma control. However, this relies on the healthcare provider’s awareness of the importance 137 
of optimal asthma management during pregnancy and their training on how to educate and 138 
support pregnant women. A recent Australian survey of general practitioners highlight a 139 
significant lack of confidence or knowledge regarding the management of asthma during 140 
pregnancy.[13] Among survey respondents, a quarter (25.8%) indicated that they would 141 
advise pregnant women to decrease or discontinue asthma medications. Inadequate 142 
management practices also extend to the hospital setting, with a previous prospective cohort 143 
study demonstrating that despite presenting to the emergency department with similar asthma 144 
severity, compared to non-pregnant women, pregnant women were less likely to be treated 145 
with oral corticosteroids and experienced a 2.9 (95%CI 1.2-6.8) times greater likelihood of 146 
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reporting an ongoing exacerbation two weeks later.[14] Such findings are not unique to 147 
medical practitioners, with a recent study involving midwives identifying feelings of 148 
uncertainty and a lack of confidence in antenatal asthma management.[15] Notably, 149 
midwives who reported having greater knowledge in asthma management also reported 150 
playing a greater role in antenatal asthma management. These studies highlight the 151 
importance of education programs targeting healthcare professionals involved in the 152 
provision of antenatal care and having integrated systems in place to ensure pregnant women 153 
with asthma receive the additional support and care they require. 154 
 155 
3.3 Physiological and Biological changes 156 
Pregnancy is a time of significant physiological change, with marked changes in 157 
kidney, liver, cardiovascular, respiratory and immunological function orchestrated by 158 
alterations in the endocrine system and the release of various hormones and growth factors 159 
into the maternal circulation by the placenta.[16] Such adaptations aim to provide an optimal 160 
environment for the fetus to grow and develop, yet data suggests asthma may worsen in 161 
pregnancy due to these physiological adaptations. Immunological adaptations are the most 162 
studied and likely factors contributing towards worsening asthma control in pregnancy. 163 
Pregnancy induced changes in immune function may promote worsening of asthma control 164 
via the activation of chemokine pathways and increased circulating levels of monocytes and 165 
neutrophils (Osei-Kumah et al 2005, 2008. 2009).[17, 18]  Furthermore there is increasing 166 
evidence of several sex-specific strategies by which the fetus copes with presence of maternal 167 
asthma in utero.[19] These adaptations have recognised importance for the management of 168 
maternal asthma during pregnancy.  169 
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Fetal sex has been implicated as a risk factor for worsening asthma in pregnancy, with 170 
pregnant women carrying a female fetus having poorer asthma control compared to women 171 
carrying a male fetus.[20] While the exact mechanism linking fetal sex with maternal asthma 172 
control remains uncertain, it is hypothesised that it may occur through sex specific 173 
differences in placental function that differentially influence maternal physiology and the 174 
course of maternal asthma in pregnancy. The sex specific differences in placental function in 175 
pregnancies complicated by asthma may also influence neonatal outcomes. Some of these 176 
differences could be due to noted sex-specific differences in placental growth, development 177 
and function, including nutrient transport, energy metabolism, and endocrine function.[21] A 178 
large body of data has demonstrated that male and female placentae adapt differently to the 179 
presence of maternal asthma by adjusting placental sensitivity to endogenous glucocorticoids 180 
and affecting placental glucocorticoid regulated pathways that are central to fetal growth and 181 
development.[22] In short, males induce a state of glucocorticoid resistance in response to 182 
maternal asthma in order to continue to grow in an adverse environment. This adaptation 183 
poses a significant risk in presence of an acute asthma exacerbation with males more likely to 184 
deliver preterm, be growth restricted or stillborn. Females remain sensitive to the effects of 185 
glucocorticoids which result in reduced growth but a greater chance of surviving to term if 186 
mothers exacerbate.[22] Most importantly, the control of maternal asthma with ICS is 187 
protective against these sex specific effects and both and male and female fetuses grow 188 
normally when asthma is controlled and outcomes are comparable to a non-asthmatic 189 
population.[23] These data suggest fetal sex may pose a challenge not only in influencing the 190 
course of asthma during pregnancy, but also in influencing its impact on subsequent 191 
pregnancy outcomes. Given evidence that the course of pregnancy and its associated adverse 192 
impacts may be influenced by fetal sex, this highlights that subsequent investigation of 193 
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interventions aimed at improving perinatal outcomes should consider fetal sex in their 194 
evaluation.  195 
The previously outlined physiological changes that occur during pregnancy can also 196 
introduce challenges in the assessment of asthma, with pregnancy-related factors such as 197 
dyspnoea of pregnancy, which can occur in up to 70% of pregnancy women, potentially 198 
confused with asthma-related symptoms.[6] Theoretically, hormonal, metabolic, and 199 
physiological changes during pregnancy could alter the mechanics of breathing and 200 
pulmonary function in pregnant women which may change across the duration of pregnancy, 201 
but evidence relating to the magnitude and significance of such changes is unclear and often 202 
inconsistent.[24] Therefore, at this stage the general recommendations are that lung function 203 
can be assessed and monitored as for non-pregnant adults, with the exception of methacholine 204 
challenge testing which is not recommended during pregnancy.[6] Beyond direct evaluation 205 
of pulmonary function, there are a range of tools available for evaluating asthma control in 206 
adults, but concerns regarding their applicability and validity for use in pregnancy have been 207 
raised due to challenges related to attributing symptoms to pregnancy or underlying 208 
asthma.[25] Most recently, however, a modified version of the Asthma Control Test, where 209 
additional focus is placed on identifying shortness of breath due to asthma rather than 210 
dyspnoea of pregnancy, has been demonstrated as being reliable and valid for evaluating 211 
asthma control in pregnancy.[25]  212 
3.4 Lifestyle changes 213 
Pregnancy is a time when women commonly enact a range of positive behavioural changes, 214 
frequently out of desire to improve outcomes of their unborn child and often with the support 215 
and encouragement of antenatal care providers. Examples of such include reduction or 216 
cessation of cigarette use or changes in diet and exercise.  217 
Author’s Post-Print Version; Copyright – Pharmacol Res; doi: 10.1016/j.phrs.2017.12.019 
11 
 
Smoking cessation in particularly has been a major focus of educational programs offered 218 
within antenatal care settings. Given the associated harmful impacts of smoking on asthma 219 
control, interventions focused on smoking cessation among asthmatic women are likely to be 220 
even more effective in improving health outcomes.[26] How these benefits are obtained, 221 
however, requires greater attention. According to data from a prospective cohort study of 222 
asthmatic women, 29% of smokers ceased smoking during early pregnancy through usual 223 
antenatal care support mechanisms.[27] In contrast, among those who received additional 224 
support through a nurse-led antenatal asthma management program, 54% stopped smoking in 225 
early pregnancy. Therefore, the impact of various smoking cessation strategies may vary 226 
dramatically in terms of how they operate and target individuals, but should remain a key 227 
focus for improving perinatal outcomes in asthmatic pregnancies.  228 
Maternal diet represents another area where changes commonly occur during pregnancy.[28] 229 
These changes include alterations in consumption (both increases and decreases) of certain 230 
foods (e.g. reduction in foods at risk of listeria or mercury contamination, increase in healthy 231 
foods such as fruit) as well as general increases in dietary supplement intake (e.g. folate, 232 
vitamin D, omega 3 fatty acids, iodine, multivitamins).[29] Such changes in dietary intakes 233 
could have important implications for alterations in asthma control during pregnancy. Some 234 
of these changes have been hypothesised to occur through alterations in oxidative stress.[30] 235 
Dietary intervention studies among non-pregnant adults have demonstrated protective 236 
impacts of antioxidants in asthma, but no such studies have been undertaken in 237 
pregnancy.[30] Observational data are available, however, to support such an intervention, 238 
with evidence that pregnant women with moderate to severe asthma have altered circulating 239 
concentrations of antioxidants compared to women with mild or no asthma, whereas low 240 
antioxidant concentrations were associated with reduced fetal growth among asthmatic 241 
pregnancies.[31] In addition, while the impact of dietary patterns has not been extensively 242 
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explored in pregnancy, pre-conception intake of a high fat/sugar/takeaway diet has been 243 
associated with an increased likelihood of uncontrolled asthma during pregnancy.[32]   244 
Lastly, interventions aimed at improving exercise in pregnancy have demonstrated positive 245 
effects in reducing the risk of excessive gestation weight gain and risk of adverse pregnancy 246 
complications.[33] While data on the impacts of such exercise interventions on asthma 247 
control in pregnancy are absent, a recent randomized controlled trial in non-pregnant obese 248 
adults demonstrated that the addition of exercise to a short-term weight-loss program led to 249 
significant improvements in asthma control and anti-inflammatory biomarkers, as well as 250 
reductions in airway and systemic inflammation.[34] Therefore, further research to identify 251 
whether dietary and exercise interventions can improve asthma control in pregnancy are 252 
warranted.  253 
 254 
3.5. Co-morbidities 255 
Comorbidities are common and are being increasingly recognized as playing an 256 
important role in influencing outcomes in individuals with asthma. Such common 257 
comorbidities include gastro-esophageal reflux disease, mental illness, obesity, and allergic 258 
rhinitis. While some of these factors may not appear immediately modifiable, especially 259 
within an obstetric setting, awareness of the contribution of these factors to impaired asthma 260 
control is important. Just as concerns regarding medication safety can impact on adherence to 261 
asthma medications during pregnancy, they could also have the same effect on medications 262 
used in the management of other co-morbidities. Clinicians should be aware of the increased 263 
likelihood of these co-morbidities among women with asthma and the requirement for 264 
comprehensive assessment, treatment, or referral as appropriate. 265 
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Rhinitis is perhaps one of the most common co-morbidities. In a recent prospective 266 
clinical trial, rhinitis occurred in 65% of pregnant asthmatic women , with 20% of women 267 
experiencing rhinitis only during pregnancy.[35] While rhinitis symptoms improved as 268 
pregnancy progressed, the presence of rhinitis was associated with poorer asthma control and 269 
anxiety. Further, atopic rhinitis was associated with poorer lung function. A separate study in 270 
the same cohort of women identified a higher prevalence of asthma exacerbations among 271 
women who were overweight (51%) or obese (48%) compared with healthy weight women 272 
(25%; P=0.026).[36] Pregnancy related weight gain appeared to have no impact on 273 
exacerbation risk.[36] Further investigations revealed that maternal overweight or obesity 274 
was associated with altered macrophage activation and that altered macrophage activation 275 
was associated with an increased risk of exacerbations requiring oral corticosteroids.[36]  276 
A prospective cohort study undertaken within a socially disadvantaged population in 277 
Australia identified that women with a self-reported history of depression or anxiety were 278 
much more likely to experience poor asthma control during pregnancy.[37] These findings 279 
are supported by those of two previous studies which identified that anxiety was an 280 
independent risk factor for poor asthma control and exacerbations.[38, 39] Further, women’s 281 
perception of asthma control in early pregnancy reduced the risk of subsequent 282 
exacerbations.[39]  It is unclear whether these associations are reflective of behavioural, 283 
social, or biological factors or the combination of all three associated with the presence of a 284 
mental health illness. What evidence it does provide, however, is the identification of a group 285 
of higher risk  women who are already recognised at being at increased risk of adverse 286 
perinatal outcomes and so could benefit from additional attention and support. Strategies 287 
aimed at addressing such key psychosocial factors, such as reducing treatment-related 288 
anxiety, may help improve asthma control and related pregnancy outcomes.  289 
 290 
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4. Interventions for improving asthma management in pregnancy 291 
An improved understanding of the unique interplay between pregnancy and asthma has led to 292 
the investigation of strategies aimed at improving asthma related outcomes. While a number 293 
of different interventions have been trialed, including self-management education, and 294 
individualized asthma management plans according to airway inflammation status, there is a 295 
lack of data associating these interventions with improvements in perinatal outcomes.[40]  296 
 297 
4.1 Asthma Education and Self-Management Skills 298 
Self-management programs are designed to facilitate the acquisition of preventive or 299 
therapeutic health care activities by patients through the provision of education by healthcare 300 
professionals which in turn assists in the adoption of health-promoting behaviours.[41] A 301 
number of studies have investigated the impact of providing asthma self-management 302 
education in pregnancy on asthma related outcomes.[12, 27, 42, 43] These services 303 
incorporate education, self-monitoring, regular review with optimisation of pharmacotherapy, 304 
and written asthma action plans for management of unstable asthma. In one prospective non-305 
comparative study, pregnant women were identified as having high levels of non-adherence, 306 
inadequate knowledge of asthma inhaler technique, and insufficient knowledge of asthma 307 
management strategies.[12] Further, less than 20% of women reported having an asthma 308 
action plan to assist them in the management of exacerbations during pregnancy.[12] The 309 
intervention itself was effective in improving skills and knowledge about asthma during 310 
pregnancy. A more recent prospective before-after study reported on the impact of the 311 
introduction of a nurse-led antenatal asthma management service on asthma related outcomes 312 
during pregnancy.[27] The introduction of this service was associated with a reduction in loss 313 
of control (RR 0.67; 95%CI 0.46-0.99), persistent uncontrolled asthma (RR 0.48; 95%CI 314 
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0.26-0.90), and asthma exacerbations (RR 0.69; 95%CI 0.33-1.42).[27] The prevalence of 315 
exacerbations reduced from 19.1% to 15% (p=0.48) following the intervention. The most 316 
robust evidence for the impact of antenatal asthma self-management education comes from a 317 
recent Australian randomised controlled trial. This involved randomisation of 60 women with 318 
asthma at less than 20 week’s gestation to receive either usual care or a pharmacist-led 319 
asthma management intervention. The intervention consisted of multidisciplinary care, 320 
education and regular monthly monitoring throughout pregnancy and was associated with a 321 
subsequent reduction in asthma control questionnaire (ACQ) scores at 3 months (-0.22 322 
95%CI: -0.54, 0.10) and 6 months (-0.60 95%CI -0.85, -0.36) compared to those receiving 323 
usual care.[42] Notably, no women in either group reported experiencing any exacerbations 324 
during the study, despite the noted differences in asthma control.  325 
Awareness of the benefits of improved asthma control through regular self-monitoring of 326 
symptoms and self-management according to a written asthma action plan led to the trial of a 327 
telehealth based intervention in pregnant asthmatics.[43] In this study the use of a mobile 328 
smartphone based application, which utilised a handheld respiratory device to support women 329 
in regularly monitoring their asthma and provided advice on how to management a 330 
deterioration in symptoms, was effective in improving asthma control over a 6-month follow-331 
up period.[43] The major benefit of such an approach was that it removed the necessity for 332 
face-to-face visits and removing such barriers to care, with data on asthma symptoms 333 
electronically communicated to treating healthcare professionals enabling intervention where 334 
necessary. Importantly, while improvements in asthma control were identified across these 335 
studies, there was no evidence of associated improvements in perinatal outcomes.  336 
 337 
4.2. Individualisation of asthma treatments 338 
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In recent years there has been growing interest in the identification and examination 339 
of differing asthma phenotypes.[44] The identification of such phenotypes has offered 340 
promise for the potential identification of those more likely to respond to a particular 341 
treatment or management strategy. There exists a number of examples demonstrating the 342 
success of such an approach.  343 
For example, the presence of airway eosinophilia (which is associated with an inflammatory 344 
phenotype) is associated with more favourable response to corticosteroid therapy,[45-47] and 345 
a greater risk of exacerbations when corticosteroids are withdrawn.[48] In contrast, 346 
administration of ICS to individuals with non-eosinophilic asthma has been associated with a 347 
significantly poorer response to treatment and an increased likelihood of poor response to 348 
inhaled corticosteroids. [45, 46] 349 
Such findings have stimulated interest in the identification of airway inflammation and its use 350 
as a tool to better guide asthma treatments. This approach was applied in pregnancy in the 351 
Managing Asthma in Pregnancy (MAP) study, which utilised the fraction of exhaled nitric 352 
oxide (FENO) and asthma symptoms to guide treatment decisions.[49] The use of this novel 353 
non-invasive approach was associated with a substantial reduction in the prevalence (41% vs. 354 
25%; p=0.011) and incidence (incidence rate ratio 0.50, 95% CI 0.33–0.76; p=0.001) of 355 
women experiencing exacerbations during pregnancy.[49] A reduction in neonatal 356 
hospitalisations was also observed (n=8 [8%] vs 18 [17%]; p=0.046), but the study was 357 
specifically powered to look at perinatal outcomes. This, however, is the focus of a larger 358 
ongoing study which will recruit a much larger number of women and focus on whether this 359 
approach leads to improvements in perinatal health outcomes.[50] This ongoing study will 360 
also include women who smoke, which will address an important limitation from the 361 
previous study as smokers were excluded. Given the high proportion of asthmatic women 362 
who also smoke during pregnancy (>20%),[26] examining efficacy of this intervention 363 
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among these women is important to guide clinical practice. Notably, use of FENO to guide 364 
asthma treatment is not a stand-alone approach and does not replace the need for appropriate 365 
asthma self-management education.  366 
 367 
 368 
4.3. Additional considerations for asthma management in pregnancy 369 
4.3.1. Optimal target for improving outcomes of asthmatic pregnancies 370 
While significant focus lies on improving asthma control during pregnancy, how asthma 371 
control is evaluated and defined remains a significant challenge for clinical practice and in 372 
clinical trials. Tools such as the ACQ or asthma control test (ACT) are commonly utilised in 373 
the evaluation of asthma control at a specific point in time,[25, 51] but there is an absence of 374 
tools available for evaluating asthma exacerbations.[52, 53] Asthma exacerbations are rather 375 
commonly classified based on specific events, such as requirement for hospital admission, 376 
emergency department presentation, unscheduled doctor visits, or receipt of oral 377 
corticosteroid course. The concern lies in how well such events reflect asthma control 378 
throughout pregnancy.[54] For example, women with poor self-awareness may not even 379 
recognise that their asthma control is deteriorating and may therefore not seek additional 380 
help, while the opposite may be true for those with greater self-awareness who may seek help 381 
much earlier. Therefore, while the presence of an asthma exacerbation during pregnancy has 382 
been associated with increased risks of adverse perinatal outcomes, data are limited on the 383 
relative impact of asthma control evaluated independently of asthma exacerbations.[54] 384 
Exacerbations identified during pregnancy likely reflect a surrogate marker for uncontrolled 385 
asthma during pregnancy, but their relative predictive value in identifying women with 386 
persistently poorly controlled asthma during pregnancy may be altered by the characteristics 387 
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of the population being studied. The requirement for greater focus on asthma control comes 388 
from recent findings of a prospective cohort study undertaken among a socially 389 
disadvantaged population, where asthma control, but not exacerbations, were associated with 390 
adverse perinatal outcomes.[8] When directly assessed in the clinical setting, many women 391 
were identified as having persistent uncontrolled asthma which could be considered a current 392 
exacerbation, but they had a lack of self-awareness to identify the extent of their symptoms or 393 
had simply ignored them. Such observations raise the possibility that direct evaluation of 394 
asthma control may have greater validity in predicting subsequent pregnancy outcomes than 395 
just exacerbations reported alone, but this remains to be determined.  396 
 397 
4.3.2. Timing of interventions in pregnancy 398 
The delay between the actual beginning of pregnancy, i.e. the time that women find out that 399 
they are pregnant to the time at which they begin to receive antenatal care, represents a likely 400 
challenge for improving perinatal outcomes in asthmatic pregnancies. The reality is that 401 
insufficient data are available to determine which periods of pregnancy are critical for 402 
optimised asthma control to reduce the risk of adverse outcomes. There is the potential that 403 
adverse outcomes could differ according to uncontrolled asthma in early pregnancy versus later 404 
pregnancy, highlighting an important area for future research. Such evidence would help 405 
identify critical periods of pregnancy to intervene to improve health outcomes. Currently, 406 
intervention studies have included women up until 20 weeks’ gestation.[42, 49] While this may 407 
still be beneficial in improving asthma control in the second half of pregnancy, a recent 408 
prospective cohort study identified that 50% of asthma exacerbations occurred in women prior 409 
to 20 weeks’ gestation, [8] highlighting the potential importance of earlier intervention 410 
strategies. 411 
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One approach lies in targeting asthma interventions as soon as women identify that they are 412 
pregnant, which may occur following an early visit to their GP for confirmation of pregnancy 413 
or antenatal booking appointment in the hospital, but for many this may still not occur until 414 
later into the second trimester. The other approach lies in ensuring initiatives are in place to 415 
encourage optimal asthma management among women of childbearing potential, such that they 416 
enter pregnancy in the best possible position. With previous research identifying that less than 417 
20% of women entered pregnancy with an established asthma action plan,[12] this represents 418 
a key objective for identifying improvements in pre-conception based initiatives. 419 
  420 
5. Conclusion 421 
 422 
Overall, pregnancy represents a significant opportunity to optimize asthma therapy and 423 
maximize lung function in order to reduce the risk of acute exacerbations and resultant adverse 424 
perinatal outcomes. However, despite knowledge of the harms associated with asthma during 425 
pregnancy little has been done to improve its management and reduce associated perinatal 426 
morbidity and mortality within the antenatal setting. This lack of progress is largely based on 427 
a lack of high-quality studies on the management of maternal asthma and where studies do 428 
exist, they typically focus on surrogate markers of maternal wellbeing, including asthma 429 
control and exacerbations. The assumption has been that improving maternal asthma control 430 
will in turn lead to improved perinatal health outcomes, but whether this is realistic is unclear 431 
and existing evidence does not support clear improvements in perinatal health outcomes 432 
associated with any maternal asthma management intervention.  433 
In the absence of such data to support specific interventions, it is important that maternal 434 
asthma is recognised within the antenatal setting as a contributing factor towards adverse 435 
pregnancy outcomes. This means that optimising asthma control should be a high priority 436 
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within the antenatal setting, with women advised about the importance of good asthma 437 
control, managing asthma actively throughout pregnancy by utilising their asthma 438 
medications, and managing exacerbations in a timely and effective manner.  439 
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Table 1. Overview of medications used in the management of asthma during pregnancy[6, 55] 579 
Medication Usual Dose Safety Data in 
Pregnancy 
Inhaled bronchodilators   
Short-acting bronchodilators  Reassuring human 
data Salbutamol/albuterol 100-200 mcg when required 
Terbutaline 500-1500 mcg when required 





Salmeterol 25-50 mcg twice daily 
Eformoterol 6-12 mcg twice daily 
Vilanterol 25 mcg once daily 




preferred due to 
greater experience 
Beclomethasone Low: 100-200 mcg/day 
Medium: >200-400 mcg/day 
High: >400 mcg/day 
Budesonide Low: 200-400 mcg/day 
Medium: >400-800 mcg/day 
High: >800 mcg/day 
Ciclesonide Low: 80-160 mcg/day 
Medium: >160-320 mcg/day 
High:>320 mcg/day 
Fluticasone propionate Low: 100-200 mcg/day 
Medium: >200-500 mcg/day 
High: >500 mcg/day 
Systemic corticosteroids 
 
 Use of systematic 
corticosteroids 
associated with 
increased risk of oral 





but likely confounded 
by maternal asthma 
severity 
Prednisolone Exacerbation: 37.5-50 mg once daily 
for 5-10 days 




 Limited experience; 
reassuring human data 
available Montelukast 10 mg daily 
Zafirlukast 20 mg twice daily 
Other treatments   
Omalizumab 75-375 mg every 2-4 weeks 
(dose according to weight and serum 
total IgE level) 
Limited experience; 
reassuring human data 
Theophylline 400-600 mg/day  
(dose according to theophylline level) 
Reassuring human 
data; limited role in 
practice due to 
monitoring 
requirements and 
associated risk of 
toxicity 
¤ Some available individually and in combination with ICS; should not be used for monotherapy 
 580 





Figure 2. Stepped approach to adjusting asthma preventer therapy during pregnancy* 583 
    ‼ 6 
High-dose ICS + LABA + oral corticosteroid      
    ↗ OR Omalizumab† ↘     
   ‼ 5 
High-dose ICS + LABA     
   ↗ OR Omalizumab† ↘    
  ‼ 4 
Medium-dose ICS + LABA    
  ↗ OR Medium-dose ICS + LRTA OR theophylline¤ ↘   
 ‼ 3 
Medium-dose ICS   
 ↗ OR Low-dose ICS + either LABA, LTRA OR theophylline¤ ↘  
‼ 2 Low-dose ICS  ↗ OR LRTA, theophylline¤  
1 None  
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LRTA, leukotriene receptor antagonist 
‼ Before stepping up, check symptoms are due to asthma, inhaler technique is correct, and adherence is 
adequate 
↗ Consider stepping up if good control is not achieved 
↘ The relative safety of stepping down in pregnancy has not been well studied and must be balanced against the 
potential harms of worsening asthma control. Consider stepping down only if the woman is taking an 
inappropriately high dose of a medicine.  
 
¤ Theophylline is a less desirable alternative during pregnancy due to need to monitor serum concentration levels 
and increased risk of adverse events 
† Restricted under specialist use for allergic asthma 
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Figure 1. Interdependence of factors influencing asthma management with a focus on optimising asthma 612 
control during pregnancy 613 
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